Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study

Shaji K. Kumar; Thierry Facon; Saad Z Usmani; Torben Plesner; Robert Z Orlowski; Cyrille Touzeau; Supratik Basu; Nizar J Bahlis; Hartmut  Goldschmidt; Michael E. O'Dwyer; Christopher P. Venner; Katja Weisel; Cyrille Hulin; Lionel Karlin; Meir  Preis; Annemiek  Broyl; William Renwick; Markus Hansson; Maria Krevvata; Jianping Wang; Rian Van Rampelbergh; Jon Ukropec; Clarissa M Uhlar; Rachel Kobos; Aurore Perrot

doi:10.1182/blood-2020-134847

Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study

Shaji K. Kumar, Thierry Facon, Saad Z Usmani, Torben Plesner, Robert Z Orlowski, Cyrille Touzeau, Supratik Basu, Nizar J Bahlis, Hartmut Goldschmidt, Michael E. O'Dwyer, Christopher P. Venner, Katja Weisel, Cyrille Hulin, Lionel Karlin, Meir Preis, Annemiek Broyl, William Renwick, Markus Hansson, Maria Krevvata, Jianping WangRian Van Rampelbergh, Jon Ukropec, Clarissa M Uhlar, Rachel Kobos, Aurore Perrot

IRS - Sygehus Lillebælt, Forskningsenhed for Hæmatologi (Vejle)

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Originalsprog	Engelsk
Tidsskrift	Blood
Vol/bind	136
Udgave nummer	Suppl. 1
Sider (fra-til)	24-26
ISSN	0006-4971
DOI	https://doi.org/10.1182/blood-2020-134847
Status	Udgivet - 5. nov. 2020

Dokumenter og links

10.1182/blood-2020-134847

Citationsformater

Kumar, S. K., Facon, T., Usmani, S. Z., Plesner, T., Orlowski, R. Z., Touzeau, C., Basu, S., Bahlis, N. J., Goldschmidt, H., O'Dwyer, M. E., Venner, C. P., Weisel, K., Hulin, C., Karlin, L., Preis, M., Broyl, A., Renwick, W., Hansson, M., Krevvata, M., ... Perrot, A. (2020). Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study. Blood, 136(Suppl. 1), 24-26. https://doi.org/10.1182/blood-2020-134847

@article{759b1ed9007a4979aee0a6813dcdb163,

title = "Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study",

author = "Kumar, {Shaji K.} and Thierry Facon and Usmani, {Saad Z} and Torben Plesner and Orlowski, {Robert Z} and Cyrille Touzeau and Supratik Basu and Bahlis, {Nizar J} and Hartmut Goldschmidt and O'Dwyer, {Michael E.} and Venner, {Christopher P.} and Katja Weisel and Cyrille Hulin and Lionel Karlin and Meir Preis and Annemiek Broyl and William Renwick and Markus Hansson and Maria Krevvata and Jianping Wang and {Van Rampelbergh}, Rian and Jon Ukropec and Uhlar, {Clarissa M} and Rachel Kobos and Aurore Perrot",

year = "2020",

month = nov,

day = "5",

doi = "10.1182/blood-2020-134847",

language = "English",

volume = "136",

pages = "24--26",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier",

number = "Suppl. 1",

}

Kumar, SK, Facon, T, Usmani, SZ, Plesner, T, Orlowski, RZ, Touzeau, C, Basu, S, Bahlis, NJ, Goldschmidt, H, O'Dwyer, ME, Venner, CP, Weisel, K, Hulin, C, Karlin, L, Preis, M, Broyl, A, Renwick, W, Hansson, M, Krevvata, M, Wang, J, Van Rampelbergh, R, Ukropec, J, Uhlar, CM, Kobos, R & Perrot, A 2020, 'Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study', Blood, bind 136, nr. Suppl. 1, s. 24-26. https://doi.org/10.1182/blood-2020-134847

Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study. / Kumar, Shaji K.; Facon, Thierry; Usmani, Saad Z et al.
I: Blood, Bind 136, Nr. Suppl. 1, 05.11.2020, s. 24-26.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

TY - ABST

T1 - Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM)

T2 - The Phase 3 Maia Study

AU - Kumar, Shaji K.

AU - Facon, Thierry

AU - Usmani, Saad Z

AU - Plesner, Torben

AU - Orlowski, Robert Z

AU - Touzeau, Cyrille

AU - Basu, Supratik

AU - Bahlis, Nizar J

AU - Goldschmidt, Hartmut

AU - O'Dwyer, Michael E.

AU - Venner, Christopher P.

AU - Weisel, Katja

AU - Hulin, Cyrille

AU - Karlin, Lionel

AU - Preis, Meir

AU - Broyl, Annemiek

AU - Renwick, William

AU - Hansson, Markus

AU - Krevvata, Maria

AU - Wang, Jianping

AU - Van Rampelbergh, Rian

AU - Ukropec, Jon

AU - Uhlar, Clarissa M

AU - Kobos, Rachel

AU - Perrot, Aurore

PY - 2020/11/5

Y1 - 2020/11/5

U2 - 10.1182/blood-2020-134847

DO - 10.1182/blood-2020-134847

M3 - Conference abstract in journal

SN - 0006-4971

VL - 136

SP - 24

EP - 26

JO - Blood

JF - Blood

IS - Suppl. 1

ER -